Using strategic planning to address hurdles in biosimilar development programs from the outset.
Rodeina Challand
Advertisement
Articles by Rodeina Challand
A number of top-selling biological products in key therapeutic areas such as cancer, diabetes, and rheumatoid arthritis have recently lost, or will soon lose, patent protection.
Advertisement
Latest Updated Articles
Operational Challenges for Biosimilar StudiesPublished: March 17th 2016 | Updated:
- Operational Challenges for Biosimilar Studies
Published: October 1st 2016 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Future-Proofing Clinical Trial Supply Chains Against Tariff Risks
2
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
3
Reframing the IND: From Tactical Requirement to Strategic Opportunity
4
Streamlining Trial Design to Accelerate Data Delivery and Investor Confidence
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
